Description: Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. As of November 20, 2024, Exscientia plc operates as a subsidiary of Recursion Pharmaceuticals, Inc..
Home Page: www.exscientia.ai
The SchrOedinger Building
Oxford,
OX4 4GE
United Kingdom
Phone:
44 18 6581 8941
Officers
| Name | Title |
|---|---|
| Dr. David Hallett Ph.D. | Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director |
| Dr. John P. Overington Ph.D. | Chief Technology Officer |
| Ms. Sara Sherman | Vice President of Investor Relations |
| Mr. Dan Ireland | Executive VP of Legal & Company Secretary |
| Mr. Parker Moss | Executive Vice President of Corporate Development |
| Ms. Caroline Rowland | Chief People Officer |
| Mr. Richard Law | Chief Business Officer |
| Mr. Nikolaus Krall | Executive Vice President of Precision Medicine |
| Dr. Marie-Louise Helena Fjallskog M.D., Ph.D. | Interim Chief Medical Officer & Clinical Development Lead |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8574 |
| Price-to-Sales TTM: | 35.0137 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 483 |